SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

被引：355

作者：

Corbett, Kizzmekia S. ^{[1
]}

Edwards, Darin K. ^{[2
]}

Leist, Sarah R. ^{[3
]}

Abiona, Olubukola M. ^{[1
]}

Boyoglu-Barnum, Seyhan ^{[1
]}

Gillespie, Rebecca A. ^{[1
]}

Himansu, Sunny ^{[2
]}

Schafer, Alexandra ^{[3
]}

Ziwawo, Cynthia T. ^{[1
]}

DiPiazza, Anthony T. ^{[1
]}

Dinnon, Kenneth H. ^{[3
]}

Elbashir, Sayda M. ^{[2
]}

Shaw, Christine A. ^{[2
]}

Woods, Angela ^{[2
]}

Fritch, Ethan J. ^{[4
]}

Martinez, David R. ^{[3
]}

Bock, Kevin W. ^{[5
]}

Minai, Mahnaz ^{[5
]}

Nagata, Bianca M. ^{[5
]}

Hutchinson, Geoffrey B. ^{[1
]}

Wu, Kai ^{[2
]}

Henry, Carole ^{[2
]}

Bahl, Kapil

Garcia-Dominguez, Dario ^{[2
]}

Ma, LingZhi ^{[2
]}

Renzi, Isabella ^{[2
]}

Kong, Wing-Pui ^{[1
]}

Schmidt, Stephen D. ^{[1
]}

Wang, Lingshu ^{[1
]}

Zhang, Yi ^{[1
]}

Phung, Emily ^{[1
,6
]}

Chang, Lauren A. ^{[1
]}

Loomis, Rebecca J. ^{[1
]}

Altaras, Nedim Emil ^{[2
]}

Narayanan, Elisabeth ^{[2
]}

Metkar, Mihir ^{[2
]}

Presnyak, Vlad ^{[2
]}

Liu, Cuiping ^{[1
]}

Louder, Mark K. ^{[1
]}

Shi, Wei ^{[1
]}

Leung, Kwanyee ^{[1
]}

Yang, Eun Sung ^{[1
]}

West, Ande ^{[3
]}

Gully, Kendra L. ^{[3
]}

Stevens, Laura J. ^{[7
]}

Gully, Kendra L. ^{[3
]}

Wang, Nianshuang ^{[8
]}

Wrapp, Daniel ^{[8
]}

Doria-Rose, Nicole A. ^{[1
]}

Stewart-Jones, Guillaume ^{[2
]}

机构：

[1] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[2] Moderna Inc, Cambridge, MA USA

[3] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA

[4] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA

[5] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[6] George Washington Univ, Inst Biomed Sci, Washington, DC USA

[7] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA

[8] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA

[9] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

来源：

NATURE | 2020年 / 586卷 / 7830期

关键词：

MERS-COV; SPIKE; INFLUENZA; IMMUNOGENICITY; PROTECTION; VIRUS; RSV;

D O I：

10.1038/s41586-020-2622-0

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.

引用

页码：567 / +

页数：21

共 50 条

[41] Orbital inflammatory disease following mRNA SARS-CoV-2 vaccine
Grunenwald, Solange
Lethellier, Gabriel
Imbert, Philippe
Dekeister, Celine
Caron, Philippe
CLINICAL CASE REPORTS, 2022, 10 (06):
[42] Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2
Atanasova, Mariyana
Dimitrov, Ivan
Ralchev, Nikola
Markovski, Aleksandar
Manoylov, Iliyan
Bradyanova, Silviya
Mihaylova, Nikolina
Tchorbanov, Andrey
Doytchinova, Irini
PHARMACEUTICALS, 2024, 17 (11)
[43] Adaptation-Proof SARS-CoV-2 Vaccine Design
Vishweshwaraiah, Yashavantha L.
Hnath, Brianna
Rackley, Brendan
Wang, Jian
Gontu, Abhinay
Chandler, Morgan
Afonin, Kirill A.
Kuchipudi, Suresh, V
Christensen, Neil
Yennawar, Neela H.
Dokholyan, Nikolay, V
ADVANCED FUNCTIONAL MATERIALS, 2022, 32 (49)
[44] Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools
da Silva, Maria Karolaynne
de Oliveira Campos, Daniel Melo
Akash, Shopnil
Akter, Shahina
Yee, Leow Chiuan
Fulco, Umberto Laino
Nobre Oliveira, Jonas Ivan
VIRUSES-BASEL, 2023, 15 (10):
[45] Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
Roberto Stellini
Renzo Gianello
Angelo Meloni
Elia Croce
Paola Materzanini
Walter Gomarasca
Infection, 2022, 50 : 791 - 793
[46] Inactivated vaccine for SARS-CoV-2
Emma Risson
Nature Reviews Immunology, 2020, 20 : 353 - 353
[47] SARS-CoV-2 mucosal vaccine
Stephanie Houston
Nature Immunology, 2023, 24 : 1 - 1
[48] SARS-CoV-2 mucosal vaccine
Houston, Stephanie
NATURE IMMUNOLOGY, 2023, 24 (01) : 1 - 1
[49] A VACCINE AGAINST SARS-COV-2
Passi, Gouri Rao
INDIAN PEDIATRICS, 2020, 57 (06) : 593 - 593
[50] Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
Stellini, Roberto
Gianello, Renzo
Meloni, Angelo
Croce, Elia
Materzanini, Paola
Gomarasca, Walter
INFECTION, 2022, 50 (03) : 791 - 793

← 1 2 3 4 5 →